9 Publications
2018
A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Turner, Nicholas C⋅Telli, Melinda L⋅Rugo, Hope S⋅Mailliez, Audrey⋅Ettl, Johannes⋅Grischke, Eva-Maria⋅Mina, Lida A⋅Balmaña, Judith⋅Fasching, Peter A⋅Hurvitz, Sara A⋅Wardley, Andrew M⋅Chappey, Colombe⋅Hannah, Alison L and Robson, Mark E
Clinical cancer research : an official journal of the American Association for Cancer Research, December 18, 2018. | Journal Article
 
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Litton, Jennifer K⋅Litton, Jennifer K⋅Rugo, Hope S⋅Rugo, Hope S⋅Ettl, Johannes⋅Ettl, Johannes⋅Hurvitz, Sara A⋅Hurvitz, Sara A⋅Gonçalves, Anthony⋅Gonçalves, Anthony⋅Lee, Kyung-Hun⋅Lee, Kyung-Hun⋅Fehrenbacher, Louis⋅Fehrenbacher, Louis⋅Yerushalmi, Rinat⋅Yerushalmi, Rinat⋅Mina, Lida A⋅Mina, Lida A⋅Martin, Miguel⋅Martin, Miguel⋅Roché, Henri⋅Roché, Henri⋅Im, Young-Hyuck⋅Im, Young-Hyuck⋅Quek, Ruben G.W⋅Quek, Ruben G W⋅Markova, Denka⋅Markova, Denka⋅Tudor, Iulia C⋅Tudor, Iulia C⋅Hannah, Alison L⋅Hannah, Alison L⋅Eiermann, Wolfgang⋅Eiermann, Wolfgang⋅Blum, Joanne L and Blum, Joanne L
The New England journal of medicine, August 15, 2018. | Journal Article
2013
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
Mina, Lida A⋅Yu, Menggang⋅Johnson, Cynthia⋅Burkhardt, Cyndi⋅Miller, Kathy D and Zon, Robin
Investigational new drugs, vol. 31, (no. 5), pp. 1307-10, 2013/Oct. | Journal Article
2011
Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients.
Appaiah, Hitesh N⋅Appaiah, Hitesh N⋅Goswami, Chirayu P⋅Goswami, Chirayu P⋅Mina, Lida A⋅Mina, Lida A⋅Badve, Sunil⋅Badve, Sunil⋅Sledge, Jr, George W⋅Sledge, George W⋅Liu, Yunlong⋅Liu, Yunlong⋅Nakshatri, Harikrishna and Nakshatri, Harikrishna
Breast cancer research : BCR, vol. 13, (no. 5), pp. R86, 2011. | Journal Article
 
Rethinking the metastatic cascade as a therapeutic target.
Mina, Lida A and Sledge, George W
Nature reviews. Clinical oncology, vol. 8, (no. 6), pp. 325-32, 2011/Jun. | Journal Article
2010
Targeted therapies in early-stage breast cancer: achievements and promises.
Sledge, George W⋅Jotwani, Aparna C and Mina, Lida A
Surgical oncology clinics of North America, vol. 19, (no. 3), pp. 669-79, 2010/Jul. | Journal Article
2009
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Mina, Lida A⋅Krop, Ian⋅Zon, Robin T⋅Isakoff, Steven J⋅Schneider, Charles J⋅Yu, Menggang⋅Johnson, Cindy⋅Vaughn, Latrice G⋅Wang, Yanping⋅Hristova-Kazmierski, Maria⋅Shonukan, Oluwatoyin O⋅Sledge, George W and Miller, Kathy D
Investigational new drugs, vol. 27, (no. 6), pp. 565-70, 2009/Dec. | Journal Article
2007
Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue
Mina, Lida A⋅Soule, Sharon E⋅Badve, Sunil S⋅Baehner, Fredrick L⋅Baker, Joffre⋅Cronin, Maureen⋅Watson, Drew⋅Mei-Lan, Liu⋅Liu, Mei-Lan⋅Sledge, George W⋅Shak, Steve and Miller, Kathy D
Breast Cancer Research and Treatment, vol. 103, (no. 2), pp. 197-208, Jun 2007. | Journal Article
2006
Twenty years of systemic therapy for breast cancer.
Mina, Lida A and Sledge, George W
Oncology (Williston Park, N.Y.), vol. 20, (no. 1), pp. 25-32; discussion 32-3, 36, 40, 2006/Jan. | Journal Article